Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cost Effectiveness and Resource Allocation
Published in: Cost Effectiveness and Resource Allocation 1/2014

Open Access 01-12-2014 | Research

System dynamics model of cervical cancer vaccination and screening interventions in Kenya

Authors: Lucy W Kivuti-Bitok, Geoff McDonnell, Roudsari Abdul, Ganesh P Pokhariyal

Published in: Cost Effectiveness and Resource Allocation | Issue 1/2014

Login to get access

Abstract

Objectives

This paper presents a simulation model for evaluating the possible effects of a screening and vaccination campaign against Human Papillomavirus [HPV] in Kenya.

Method

A System Dynamics model was developed using the iThink™ computer simulation package. The model was based on data extracted from epidemiological, demographic and published research and where data was not available, expert opinion was sought. The deterministic model stratified the population by vaccination status, screening status and HPV infection status. The model was simulated to estimate outputs for the next 50 years from 2011. Cost Utility indicators of Disability Adjusted Life Years (DALYs) and cost per averted DALY were used for economic evaluation.

Results

The model predicted that catch up vaccination had the greatest impact in reducing the prevalence of cervical cancer. This was followed by Primary vaccination, with early detection through Screening having the lowest impact of the three choices of interventions in respect of averted cases of cervical cancer and DALY estimates.

Conclusion

Kenya as a country should consider adoption of secondary /catch up vaccination as an immediate measure to curb cervical cancer followed by primary vaccination of pre-adolescent girls. Screening should be a complementary measure(s). This model provides a policy decision support vehicle that can allow for choice between different interventions based on their expected outcomes. It also allows modification to accommodate new research results and information to assess the clinical impact of different policies and interventions in cervical cancer management in Kenya.
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
5.
6.
7.
8.
Elbasha EH, Dasbach EJ, Insinga RP: Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007,13(1):28–41. 10.3201/eid1301.060438PubMedCentralPubMedCrossRef
9.
10.
11.
12.
13.
14.
15.
16.
17.
Denny L, Quinn M, Sankaranarayanan R: Chapter 8: screening for cervical cancer in developing countries. Vaccine 2006,24(Suppl 3):S3/71–77.
18.
Gakidou E, Nordhagen S, Obermeyer Z: Coverage of cervical cancer screening in 57 countries: Low average levels and large inequalities. PLoS Med 2008, 5: 6. 10.1371/journal.pmed.0050006CrossRef
19.
20.
21.
22.
23.
24.
Fett MJ: Computer modelling of the Swedish two county trial of mammographic screening and trade offs between participation and screening interval. J Med Screen 2001,8(1):39–45. 10.1136/jms.8.1.39PubMedCrossRef
25.
26.
Abbott RG, Forrest S, Pienta KJ: Simulating the hallmarks of cancer. Artif Life 2006, 12: 617–634. 10.1162/artl.2006.12.4.617PubMedCrossRef
27.
Goldhaber-Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, Goldie SJ, Salomon JA: Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr 2007., 5:
28.
Goldie SJ, Goldhaber-Fiebert JD, Garnett GP: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. (HPV Vaccines and Screening in the Prevention of Cervical Cancer.). Vaccine 2006,24(Suppl 3):S3/155–63.
29.
30.
31.
Martens JE, Smedts FMM, Ploeger D, Helmerhorst TJM, Ramaekers FCS, Arends JW, Hopman AHN: Distribution pattern and marker profile show two subpopulations of reserve cells in the endocervical canal. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol 2009, 28: 381–388. 10.1097/PGP.0b013e31819932f8CrossRef
32.
Di Bonito L, Bergeron C: Cytological screening of endocervical adenocarcinoma. Ann Pathol 2012, 32: e8-e14. 10.1016/j.annpat.2012.09.230PubMedCrossRef
33.
34.
35.
Fox-Rushby A J, Hanson K: Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan 2001,16(3):326–331. 10.1093/heapol/16.3.326CrossRef
36.
37.
Corner S: Standard error vs . Standard error of measurement. 1999,3(April):20–25.
38.
39.
40.
41.
De Visser R, Waites L, Parikh C, Lawrie A: The importance of social norms for uptake of catch-up human papillomavirus vaccination in young women. Sex Health 2011,8(3):330–337. 10.1071/SH10155PubMedCrossRef
42.
Milne RJ, Vander Hoorn S, Kulasingam S, Tan AL: Economic evaluation of female vaccination with a quadrivalent human papillomavirus vaccine in New Zealand. Value Heal 2007, 10: A6-A6.CrossRef
43.
44.
45.
Baussano I, Lazzarato F, Ronco G, Dillner J, Franceschi S: Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries. Int J Cancer 2013,133(8):1876–1881. 10.1002/ijc.28197PubMedCrossRef
46.
47.
Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS: Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009, 85: 499–502. 10.1136/sti.2009.037788PubMedCrossRef
48.
49.
Bartlett JA, Peterson JA: The uptake of human papillomavirus (HPV) vaccine among adolescent females in the united states: a review of the literature. J Sch Nurs Off Publ Natl Assoc Sch Nurses 2011, 27: 434–446.
50.
51.
Tsu V: Taking HPV, vaccination to national scale: building on experience to date. Int J Gynecol Obstet 2012, 119: S252.
52.
Kane MA, Serrano B, De Sanjosé S, Wittet S: Implementation of human papillomavirus immunization in the developing world. Vaccine 2012,30(Suppl 5):F192-F200.PubMedCrossRef
53.
54.
Hessel L: Introduction of vaccination against human papillomavirus in developing countries: update and perspectives. Med Trop Rev du Corps sante Colon 2009, 69: 323–326.
55.
56.
Kivuti-Bitok L, Pokhariyal G, Roudsari AV, McDonnell G: An exploration of opportunities and challenges facing cervical cancer managers in Kenya. BMC Res 2013,6(1):1. Available at: BMC Research Notes. Accessed August 11, 2013 10.1186/1756-0500-6-1CrossRef
Metadata
Title
System dynamics model of cervical cancer vaccination and screening interventions in Kenya
Authors
Lucy W Kivuti-Bitok
Geoff McDonnell
Roudsari Abdul
Ganesh P Pokhariyal
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cost Effectiveness and Resource Allocation / Issue 1/2014
Electronic ISSN: 1478-7547
DOI
https://doi.org/10.1186/1478-7547-12-26

Other articles of this Issue 1/2014

Cost Effectiveness and Resource Allocation 1/2014 Go to the issue

Methodology

Making use of equity sensitive QALYs: a case study on identifying the worse off across diseases

Research

Cost-effectiveness of community vegetable gardens for people living with HIV in Zimbabwe

Research

Multi-criteria decision analysis of breast cancer control in low- and middle- income countries: development of a rating tool for policy makers

Review

Health research priority setting in selected high income countries: a narrative review of methods used and recommendations for future practice

Research

Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea

Research

Economic evaluation of policy initiatives in the organisation and delivery of healthcare: a case study of gastroenterology endoscopy services